Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Gizelle Popradi, MD

Director of Hemopoietic Stem Cell Transplant program
McGill University Hospital
Montreal, Quebec, Canada

Disclosures

Gizelle Popradi, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Avir Pharma; Amgen, Inc.; Bristol Myers Squibb Company; Gilead Sciences, Inc.; Jazz Pharmaceuticals, Inc.; Kite Pharma, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; Mallinckrodt; Merck; Novartis; Pfizer, Inc.; Seagen Inc.; Sanofi; SERVIER; Taiho Pharmaceutical Co., Ltd.; Takeda
Speaker or member of speakers bureau for: Amgen, Inc.; Merck; Novartis; Pfizer, Inc.; Sanofi; Seagen Inc.
Research funding from: AbbVie Inc.; Equilium Inc; Syndax Pharmaceuticals, Inc.

Sarah Shalhoub, MD

Transplant Infectious Diseases
Department of Medicine
Assistant Professor
London Health Sciences Centre
Western University
London, Ontario, Canada

Disclosures

Sarah Shalhoub, MD, has the following relevant financial relationships:
Research funding from: I am a site investigator for the Novation-1 trial: A randomized, double-blind, placebo controlled, phase III study to evaluate the safety and efficacy of aerosolized novaferon + SOC vs. placebo + SOC in hospitalized adult patients with moderate to severe COVID-19.

Genovefa Papanicolaou, MD

Transplant ID Physician
Memorial Sloan Kettering Cancer Center
New York, New York, United States

Disclosures

Genovefa Papanicolaou, MD, has the following relevant financial relationships:
Consultant or advisor for: AlloVir; Astellas Pharma, Inc.; Cidara; CSL Behring; Merck; Octapharma; SymBio Pharmaceuticals Limited; Takeda
Research funding from: Merck; Takeda

Per Ljungman, MD

Professor Emeritus of Hematology
Karolinska Institutet
Senior Physician
Department of Cellular Therapy, Allogeneic Stem Cell Transplantation and Hematology
Karolinska University Hospital
Stockholm, Sweden

Disclosures

Per Ljungman, MD, has the following relevant financial relationships:
Consultant or advisor for: Gilead
Speaker or member of speakers bureau for: Biotest; Bristol Myers Squibb Company; Gilead Sciences, Inc. InMed Medical Communications China; Merck Sharp & Dohme; Moderna, Inc.; Takeda
Research funding from: AlloVirJanssen (former); Merck Sharp & Dohme (former); Takeda (former)
Contracted researcher for: Blueprint Pharmaceuticals (DSMB member); Enanta Pharmaceuticals, Inc. (DSMB chair); Octapharma (DSMB chair)

Editor

Maya Khalaf, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Maya Khalaf, MSc, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

Optimizing Cytomegalovirus Infection Prevention for Allogenic Hematopoietic Stem Cell Transplantation Patients

Authors: Gizelle Popradi, MD; Sarah Shalhoub, MD; Genovefa Papanicolaou, MD; Per Ljungman, MD
CME / ABIM MOC Released: 3/23/2023
Valid for credit through: 3/23/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.50 ABIM MOC points

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology/oncology specialists, infectious disease (ID)/HIV specialists, and critical care specialists.

The goal of this activity is for the learner to be better able to understand and adopt CMV prevention strategies in patients undergoing allogenic HSCT.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Mechanisms of action of the various therapies used in the treatment and prevention, including assessment of risk in CMV active infection and disease, after allogeneic HSCT
- Real-world evidence on the benefits and limitations of CMV antiviral management strategies post-allogeneic HSCT
Have greater competence related to
- Clinical guideline recommendations for the treatment and prevention of CMV infection in post-allogeneic HSCT patients

Disclosures

Faculty

Gizelle Popradi, MD

Director of Hemopoietic Stem Cell Transplant program
McGill University Hospital
Montreal, Quebec, Canada

Disclosures

Gizelle Popradi, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Avir Pharma; Amgen, Inc.; Bristol Myers Squibb Company; Gilead Sciences, Inc.; Jazz Pharmaceuticals, Inc.; Kite Pharma, Inc.; Kyowa Kirin Pharmaceutical Development, Inc.; Mallinckrodt; Merck; Novartis; Pfizer, Inc.; Seagen Inc.; Sanofi; SERVIER; Taiho Pharmaceutical Co., Ltd.; Takeda
Speaker or member of speakers bureau for: Amgen, Inc.; Merck; Novartis; Pfizer, Inc.; Sanofi; Seagen Inc.
Research funding from: AbbVie Inc.; Equilium Inc; Syndax Pharmaceuticals, Inc.

Sarah Shalhoub, MD

Transplant Infectious Diseases
Department of Medicine
Assistant Professor
London Health Sciences Centre
Western University
London, Ontario, Canada

Disclosures

Sarah Shalhoub, MD, has the following relevant financial relationships:
Research funding from: I am a site investigator for the Novation-1 trial: A randomized, double-blind, placebo controlled, phase III study to evaluate the safety and efficacy of aerosolized novaferon + SOC vs. placebo + SOC in hospitalized adult patients with moderate to severe COVID-19.

Genovefa Papanicolaou, MD

Transplant ID Physician
Memorial Sloan Kettering Cancer Center
New York, New York, United States

Disclosures

Genovefa Papanicolaou, MD, has the following relevant financial relationships:
Consultant or advisor for: AlloVir; Astellas Pharma, Inc.; Cidara; CSL Behring; Merck; Octapharma; SymBio Pharmaceuticals Limited; Takeda
Research funding from: Merck; Takeda

Per Ljungman, MD

Professor Emeritus of Hematology
Karolinska Institutet
Senior Physician
Department of Cellular Therapy, Allogeneic Stem Cell Transplantation and Hematology
Karolinska University Hospital
Stockholm, Sweden

Disclosures

Per Ljungman, MD, has the following relevant financial relationships:
Consultant or advisor for: Gilead
Speaker or member of speakers bureau for: Biotest; Bristol Myers Squibb Company; Gilead Sciences, Inc. InMed Medical Communications China; Merck Sharp & Dohme; Moderna, Inc.; Takeda
Research funding from: AlloVirJanssen (former); Merck Sharp & Dohme (former); Takeda (former)
Contracted researcher for: Blueprint Pharmaceuticals (DSMB member); Enanta Pharmaceuticals, Inc. (DSMB chair); Octapharma (DSMB chair)

Editor

Maya Khalaf, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Maya Khalaf, MSc, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

CME / ABIM MOC

Optimizing Cytomegalovirus Infection Prevention for Allogenic Hematopoietic Stem Cell Transplantation Patients

Authors: Gizelle Popradi, MD; Sarah Shalhoub, MD; Genovefa Papanicolaou, MD; Per Ljungman, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/23/2023

Valid for credit through: 3/23/2024, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Understanding CMV Infection Risk in Allogeneic HSCT

In addition to the clinical burden, did you know that CMV infection after allogeneic HSCT is associated with a significant economic burden?
Gizelle Popradi, MD

Approaches to Prophylactic and Preemptive CMV Strategies

Did you know that approximately 80% of CMV-seropositive recipients are at risk for significant CMV viremia and disease?
Sarah Shalhoub, MD

What Have We Learned From the Real-World Evidence?

Did you know that real-world outcomes of currently available standard of care demonstrated significant reductions in CMV disease and mortality?
Genovefa Papanicolaou, MD

Guideline Recommendations for the Prevention of CMV Infection in Patients Receiving Allogeneic HSCT

What are the treatment considerations for the prevention of CMV infection after allogeneic HSCT?
Per Ljungman, MD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 7

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Gizelle Popradi, MD

Sarah Shalhoub, MD

Genovefa Papanicolaou, MD

Per Ljungman, MD

Editor

Maya Khalaf, MSc

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CME / ABIM MOC

Optimizing Cytomegalovirus Infection Prevention for Allogenic Hematopoietic Stem Cell Transplantation Patients

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Gizelle Popradi, MD

Sarah Shalhoub, MD

Genovefa Papanicolaou, MD

Per Ljungman, MD

Editor

Maya Khalaf, MSc

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Optimizing Cytomegalovirus Infection Prevention for Allogenic Hematopoietic Stem Cell Transplantation Patients

Contents of This CME Activity

Understanding CMV Infection Risk in Allogeneic HSCT

Approaches to Prophylactic and Preemptive CMV Strategies

What Have We Learned From the Real-World Evidence?

Guideline Recommendations for the Prevention of CMV Infection in Patients Receiving Allogeneic HSCT

Learning Feedback Questions